US20030194807A1
(en)
*
|
1992-11-02 |
2003-10-16 |
Roberto Crea |
Walk-through mutagenesis
|
DE69331336T2
(en)
*
|
1993-04-09 |
2002-08-14 |
Catalytic Antibodies Inc |
SELECTION OF GENES CATALYTIC ANTIBODIES
|
US20060257890A1
(en)
|
1996-05-20 |
2006-11-16 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US6995017B1
(en)
|
1994-02-17 |
2006-02-07 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US5605793A
(en)
*
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
US6335160B1
(en)
|
1995-02-17 |
2002-01-01 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US6309883B1
(en)
|
1994-02-17 |
2001-10-30 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US6165793A
(en)
*
|
1996-03-25 |
2000-12-26 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5683987A
(en)
*
|
1994-07-12 |
1997-11-04 |
The Board Of Regents Of The University Of Nebraska |
Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
|
US6063562A
(en)
*
|
1994-09-16 |
2000-05-16 |
Sepracor, Inc. |
In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
|
US5602021A
(en)
*
|
1994-12-29 |
1997-02-11 |
Catalytic Antibodies, Inc. |
Method for generating proteolytic enzymes specific against a selected peptide sequence
|
US6537776B1
(en)
*
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
US20030219752A1
(en)
*
|
1995-12-07 |
2003-11-27 |
Diversa Corporation |
Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
US6939689B2
(en)
|
1995-12-07 |
2005-09-06 |
Diversa Corporation |
Exonuclease-mediated nucleic acid reassembly in directed evolution
|
US6358709B1
(en)
|
1995-12-07 |
2002-03-19 |
Diversa Corporation |
End selection in directed evolution
|
US5830696A
(en)
|
1996-12-05 |
1998-11-03 |
Diversa Corporation |
Directed evolution of thermophilic enzymes
|
US6740506B2
(en)
|
1995-12-07 |
2004-05-25 |
Diversa Corporation |
End selection in directed evolution
|
US6238884B1
(en)
|
1995-12-07 |
2001-05-29 |
Diversa Corporation |
End selection in directed evolution
|
BR9713955A
(en)
*
|
1996-12-20 |
2000-05-23 |
Unilever Nv |
Enzymatic bleaching composition, and process for bleaching stains present in fabrics.
|
US6153410A
(en)
*
|
1997-03-25 |
2000-11-28 |
California Institute Of Technology |
Recombination of polynucleotide sequences using random or defined primers
|
DE19731990A1
(en)
*
|
1997-07-25 |
1999-01-28 |
Studiengesellschaft Kohle Mbh |
Process for the production and identification of new hydrolases with improved properties
|
US6670127B2
(en)
*
|
1997-09-16 |
2003-12-30 |
Egea Biosciences, Inc. |
Method for assembly of a polynucleotide encoding a target polypeptide
|
EP1051484A1
(en)
*
|
1998-01-30 |
2000-11-15 |
Sepracor, Inc. |
Gene regulator fusion proteins and methods of using the same for determining resistance of a protein to a drug targeted there against
|
US7153655B2
(en)
*
|
1998-06-16 |
2006-12-26 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
|
US20090130718A1
(en)
*
|
1999-02-04 |
2009-05-21 |
Diversa Corporation |
Gene site saturation mutagenesis
|
EP1073710A4
(en)
*
|
1999-02-04 |
2007-12-19 |
Verenium Corp |
Non-stochastic generation of genetic vaccines and enzymes
|
JP3399518B2
(en)
*
|
1999-03-03 |
2003-04-21 |
インターナショナル・ビジネス・マシーンズ・コーポレーション |
Semiconductor structure and method of manufacturing the same
|
AU3879300A
(en)
*
|
1999-03-09 |
2000-09-28 |
Diversa Corporation |
End selection in directed evolution
|
US6251604B1
(en)
*
|
1999-08-13 |
2001-06-26 |
Genopsys, Inc. |
Random mutagenesis and amplification of nucleic acid
|
US7115712B1
(en)
|
1999-12-02 |
2006-10-03 |
Maxygen, Inc. |
Cytokine polypeptides
|
WO2001064864A2
(en)
*
|
2000-02-28 |
2001-09-07 |
Maxygen, Inc. |
Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation
|
WO2001073000A2
(en)
*
|
2000-03-24 |
2001-10-04 |
Maxygen, Inc. |
Methods for modulating cellular and organismal phenotypes
|
US8288322B2
(en)
*
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
CA2406236C
(en)
*
|
2000-04-17 |
2013-02-19 |
Dyax Corp. |
Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
|
AU2001275530A1
(en)
*
|
2000-06-08 |
2001-12-17 |
Board Of Regents, The University Of Texas System |
Inhibitors of c-reactive protein induced inflammation
|
FR2813314B1
(en)
*
|
2000-08-25 |
2004-05-07 |
Biomethodes |
MASSIVE DIRECTED MUTAGENESIS PROCESS
|
US6958213B2
(en)
|
2000-12-12 |
2005-10-25 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function
|
PT2316940E
(en)
|
2000-12-18 |
2013-10-16 |
Dyax Corp |
Focused libraries of genetic packages
|
US20020086292A1
(en)
|
2000-12-22 |
2002-07-04 |
Shigeaki Harayama |
Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
|
JP2004532038A
(en)
*
|
2001-05-17 |
2004-10-21 |
ディヴァーサ コーポレイション |
Application of novel antigen-binding molecules to therapeutic, diagnostic, prophylactic, enzymatic, industrial and agricultural fields, and methods for producing and screening novel antigen-binding molecules therefor
|
SE0102327D0
(en)
|
2001-06-28 |
2001-06-28 |
Active Biotech Ab |
A novel engineered superantigen for human therapy
|
US7647184B2
(en)
*
|
2001-08-27 |
2010-01-12 |
Hanall Pharmaceuticals, Co. Ltd |
High throughput directed evolution by rational mutagenesis
|
US20040096826A1
(en)
*
|
2002-01-30 |
2004-05-20 |
Evans Glen A. |
Methods for creating recombination products between nucleotide sequences
|
US20030224404A1
(en)
*
|
2002-02-25 |
2003-12-04 |
Manuel Vega |
High throughput directed evolution of nucleic acids by rational mutagenesis
|
US20030171543A1
(en)
*
|
2002-03-05 |
2003-09-11 |
Bott Richard R. |
High throughput mutagenesis screening method
|
US20030199068A1
(en)
*
|
2002-03-05 |
2003-10-23 |
Bott Richard R. |
High throughput mutagenesis screening method
|
JP4493347B2
(en)
*
|
2002-04-17 |
2010-06-30 |
ロベルト クレア |
Universal library of immunoglobulins
|
EP1495142B1
(en)
*
|
2002-04-17 |
2007-09-26 |
Bioren, Inc. |
"doping" in walk-through mutagenesis
|
ES2285118T5
(en)
*
|
2002-05-17 |
2012-09-21 |
Alligator Bioscience Ab |
A METHOD FOR IN VITRO MOLECULAR DEVELOPMENT OF A PROTEIC FUNCTION.
|
BR0313281A
(en)
|
2002-08-06 |
2007-07-24 |
Verdia Inc |
ap1 amine oxidase variants
|
US20040067532A1
(en)
*
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
JP4796299B2
(en)
|
2002-08-12 |
2011-10-19 |
ジェンネレックス インコーポレイティッド |
Methods and compositions for poxviruses and cancer
|
US7785799B2
(en)
*
|
2002-08-16 |
2010-08-31 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to flavivirus envelope protein domain III antigens
|
ATE466085T1
(en)
*
|
2002-09-09 |
2010-05-15 |
Hanall Pharmaceutical Co Ltd |
PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES
|
JP2007524380A
(en)
|
2003-04-02 |
2007-08-30 |
ボード オブ リージェンツ ザ ユニバーティー オブ テキサス システム |
Bik mutant with antitumor effect
|
EP2322629A3
(en)
|
2003-04-29 |
2011-11-02 |
Pioneer Hi-Bred International Inc. |
Novel glyphosate-n-acetyltransferase (GAT) genes
|
BRPI0412007A
(en)
*
|
2003-06-27 |
2006-08-15 |
Bioren Inc |
look-through mutagenesis
|
DK1664343T3
(en)
|
2003-09-09 |
2014-08-11 |
Integrigen Inc |
METHODS AND COMPOSITIONS FOR GENERATING CHIMELY HUMAN ANTIBODY GENES
|
BRPI0513155B1
(en)
*
|
2004-07-06 |
2021-07-20 |
Bioren, Inc. |
METHOD OF DISTINGUISHING ONE OR MORE FUNCTIONAL AMINO ACID RESIDUES FROM NON-FUNCTIONAL AMINO ACID RESIDUES IN A DEFINED REGION WITHIN A POLYPEPTID
|
WO2006014498A2
(en)
|
2004-07-06 |
2006-02-09 |
Bioren, Inc. |
Universal antibody libraries
|
BRPI0511448A
(en)
*
|
2004-07-06 |
2007-12-26 |
Bioren Inc |
high affinity anti-tnf-alpha antibodies, generation method and sequence library
|
WO2006114700A2
(en)
*
|
2005-04-26 |
2006-11-02 |
Bioren, Inc. |
Method of producing human igg antibodies with enhanced effector functions
|
US20070026012A1
(en)
|
2005-08-01 |
2007-02-01 |
Cornell Research Foundation, Inc. |
Compositions and methods for monitoring and altering protein folding and solubility
|
KR20090004839A
(en)
*
|
2005-09-07 |
2009-01-12 |
제네렉스, 인코포레이티드 |
Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
US8716195B2
(en)
|
2005-11-14 |
2014-05-06 |
Bioren, Inc. |
Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
|
GB2432366B
(en)
*
|
2005-11-19 |
2007-11-21 |
Alligator Bioscience Ab |
A method for in vitro molecular evolution of protein function
|
EP2522678A1
(en)
|
2006-05-15 |
2012-11-14 |
Sea Lane Biotechnologies, LLC |
Neutralizing antibodies to influenza viruses
|
US20080108513A1
(en)
*
|
2006-06-01 |
2008-05-08 |
Northwestern University |
Cellular Arrays
|
JP2010500876A
(en)
|
2006-08-18 |
2010-01-14 |
アブリンクス エン.ヴェー. |
Amino acid sequence directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6 mediated signaling
|
CA2921048C
(en)
|
2006-09-15 |
2018-06-05 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
WO2008130437A2
(en)
*
|
2006-10-20 |
2008-10-30 |
Arizona Board Of Regents For And On Behalf Of Arizona State University |
Modified cyanobacteria
|
EP2118281A2
(en)
|
2007-02-12 |
2009-11-18 |
Codexis, Inc. |
Structure-activity relationships
|
US20100106585A1
(en)
*
|
2007-04-17 |
2010-04-29 |
American Express Travel Related Services Company, Inc. |
System and method for evaluating positive behavior and offering incentives based upon limited use identifier transactions
|
AU2008287426B2
(en)
*
|
2007-08-10 |
2014-06-26 |
Protelica, Inc. |
Universal fibronectin type III binding-domain libraries
|
US8680019B2
(en)
*
|
2007-08-10 |
2014-03-25 |
Protelica, Inc. |
Universal fibronectin Type III binding-domain libraries
|
US8470966B2
(en)
|
2007-08-10 |
2013-06-25 |
Protelica, Inc. |
Universal fibronectin type III binding-domain libraries
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
EP3753947A1
(en)
|
2007-09-14 |
2020-12-23 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
AU2008328785A1
(en)
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Method for obtaining polypeptide constructs comprising two or more single domain antibodies
|
US9873957B2
(en)
*
|
2008-03-13 |
2018-01-23 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
AU2009240481B2
(en)
*
|
2008-04-24 |
2015-07-30 |
Takeda Pharmaceutical Company Limited |
Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
|
EP2383292A1
(en)
*
|
2008-05-02 |
2011-11-02 |
Novartis AG |
Improved fibronectin-based binding molecules and uses thereof
|
EP3629022A1
(en)
|
2008-07-25 |
2020-04-01 |
Richard W. Wagner |
Protein screening methods
|
JP5230397B2
(en)
*
|
2008-12-18 |
2013-07-10 |
独立行政法人科学技術振興機構 |
Method for determining antigen-binding site of anti-transmembrane protein antibody
|
WO2010111707A1
(en)
|
2009-03-27 |
2010-09-30 |
Sapphire Energy, Inc. |
Variant isoprenoid producing enzymes and uses thereof
|
WO2010115998A2
(en)
|
2009-04-10 |
2010-10-14 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
EP2417162A2
(en)
|
2009-04-10 |
2012-02-15 |
Ablynx N.V. |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
CA2764398A1
(en)
|
2009-06-05 |
2010-12-09 |
Erik Depla |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
KR101759888B1
(en)
|
2009-09-14 |
2017-07-20 |
신라젠(주) |
Oncolytic vaccinia virus combination cancer therapy
|
US20110082054A1
(en)
*
|
2009-09-14 |
2011-04-07 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr3 designs
|
US9139825B2
(en)
|
2009-10-30 |
2015-09-22 |
Novartis Ag |
Universal fibronectin type III bottom-side binding domain libraries
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
EP2510088B1
(en)
|
2009-12-10 |
2016-10-05 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
WO2011092233A1
(en)
|
2010-01-29 |
2011-08-04 |
Novartis Ag |
Yeast mating to produce high-affinity combinations of fibronectin-based binders
|
US9354228B2
(en)
|
2010-07-16 |
2016-05-31 |
Adimab, Llc |
Antibody libraries
|
CN107903321A
(en)
|
2010-07-30 |
2018-04-13 |
诺华有限公司 |
Fibronectin cradle molecule and Qi Ku
|
CA2805803A1
(en)
|
2010-08-13 |
2012-02-16 |
Pioneer Hi-Bred International, Inc. |
Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (hppd) activity
|
US9919047B2
(en)
|
2011-01-04 |
2018-03-20 |
Sillajen, Inc. |
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
|
EP2718427B1
(en)
|
2011-06-08 |
2017-01-11 |
Children's Hospital of Eastern Ontario Research Institute Inc. |
Compositions for glioblastoma treatment
|
US10138302B2
(en)
|
2011-09-23 |
2018-11-27 |
Ablynx N.V. |
Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
|
KR102434073B1
(en)
|
2011-10-11 |
2022-08-18 |
비엘라 바이오, 인크. |
Cd40l-specific tn3-derived scaffolds and methods of use thereof
|
EP2820043B1
(en)
|
2012-03-02 |
2020-01-15 |
Ablynx N.V. |
Biparatopic pseudomonas aeruginosa pcrv binding single variable domain antibodies
|
CN104411823A
(en)
|
2012-05-04 |
2015-03-11 |
纳幕尔杜邦公司 |
Compositions and methods comprising sequences having meganuclease activity
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
CA2901501C
(en)
|
2013-02-21 |
2023-03-07 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Vaccine composition
|
BR112015023272A2
(en)
|
2013-03-14 |
2017-07-18 |
Pioneer Hi Bred Int |
plant cell, plant, plant explant, transgenic seed, method for producing a plant cell having a heterologous polynucleotide encoding a polypeptide having dicamba decarboxylase activity, method for controlling weeds in a field containing a crop and method for controlling weeds in a field containing a culture
|
EP2970935A1
(en)
|
2013-03-14 |
2016-01-20 |
Pioneer Hi-Bred International, Inc. |
Compositions having dicamba decarboxylase activity and methods of use
|
EP3209327A1
(en)
|
2014-10-21 |
2017-08-30 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
EP3842451A1
(en)
|
2015-03-12 |
2021-06-30 |
MedImmune, LLC |
Method of purifying albumin-fusion proteins
|
JP6962819B2
(en)
|
2015-04-10 |
2021-11-05 |
アディマブ, エルエルシー |
Method for Purifying Heterodimer Multispecific Antibody from Parent Homodimer Antibody Species
|
JP6867302B2
(en)
|
2015-05-21 |
2021-04-28 |
フル スペクトラム ジェネティクス, インコーポレイテッド |
How to improve protein characteristics
|
CN110291402B
(en)
|
2016-06-27 |
2023-09-01 |
朱诺治疗学股份有限公司 |
Method for identifying peptide epitopes, molecules binding such epitopes and related uses
|
MA45491A
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
|
WO2018237323A1
(en)
|
2017-06-23 |
2018-12-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Pde5a destabilizing domains
|
EP3723788A4
(en)
|
2017-12-15 |
2022-04-13 |
Aleta Biotherapeutics Inc. |
Cd19 variants
|